Skip to content

News & Events

Academic Myeloma Consortium (AMyC)

Blood Journal Article – A Study Update for 10MM01: Carfilzomib and Pomalidomide with Dexamethasone in Multiple Myeloma
This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.
CORE Science Solutions, LLC. to Exhibit at 2012 ASCO and Host Meet and Greet Reception
CORE Science Solutions (CSS) Consortia, the Academic Gastrointestinal Cancer Consortium (AGICC) and Academic Myeloma Consortium (AMyC) will have a presence at the 2012 ASCO meeting June 1-4 in Chicago, IL.
AMyC presence at the 2011 ASH meeting
The Academic Myeloma Consortium (AMyC) was present at the December 2011 ASH meeting. The Consortium is part of the CORE Science Solutions (CSS) group of Consortia focused on collaborating with pharmaceutical and biotech companies on the development of drugs to treat myeloma. CSS is part of the Criterium Inc. group of companies.
Aptium Oncology Launches Myeloma Research Network as IOM Calls for Improvements in Cancer Research
Aptium Oncology, a consulting and management company for cancer centers, is putting together a network of investigators specifically focused on myeloma and related cancers. The Aptium Oncology Myeloma Consortium (AMyC) is modeled after Aptium's GI Cancer Consortium, a group launched in 2008 to focus on gastrointestinal cancers.
Aptium Oncology Launches Multi-Institutional Myeloma Consortium for Early Phase Myeloma Trials
Aptium Oncology, Inc. announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers.